Akero Therapeutics Inc (AKRO)
29.76
-1.21
(-3.91%)
USD |
NASDAQ |
Nov 14, 16:00
29.02
-0.74
(-2.49%)
After-Hours: 20:00
Akero Therapeutics Research and Development Expense (Quarterly): 72.23M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 72.23M |
| June 30, 2024 | 55.32M |
| March 31, 2024 | 50.65M |
| December 31, 2023 | 53.39M |
| September 30, 2023 | 38.63M |
| June 30, 2023 | 27.98M |
| March 31, 2023 | 21.79M |
| December 31, 2022 | 18.32M |
| September 30, 2022 | 25.09M |
| June 30, 2022 | 21.36M |
| March 31, 2022 | 20.51M |
| December 31, 2021 | 27.71M |
| September 30, 2021 | 19.47M |
| June 30, 2021 | 23.98M |
| Date | Value |
|---|---|
| March 31, 2021 | 10.60M |
| December 31, 2020 | 25.71M |
| September 30, 2020 | 17.38M |
| June 30, 2020 | 13.04M |
| March 31, 2020 | 8.791M |
| December 31, 2019 | 13.14M |
| September 30, 2019 | 13.88M |
| June 30, 2019 | 5.96M |
| March 31, 2019 | 4.063M |
| December 31, 2018 | 1.983M |
| September 30, 2018 | 1.253M |
| June 30, 2018 | 8.42M |
| March 31, 2018 | 0.226M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
8.791M
Minimum
Mar 2020
72.23M
Maximum
Sep 2024
28.25M
Average
22.88M
Median
Research and Development Expense (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 68.74M |
| 89bio Inc | 141.44M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 4.672M |
| iBio Inc | 1.14M |